MedTrace Logo

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2015-03-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.

Conditions

Interventions

DRUG

HQK-1001

HQK-1001 tablets, twice daily for 48 weeks

DRUG

Placebo

Placebo tablets, twice daily for 48 weeks

Sponsors & Collaborators

  • HemaQuest Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Ghalie, MD, MBA · HemaQuest Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • United States
  • Canada
  • Egypt
  • Jamaica
  • Lebanon

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601340 on ClinicalTrials.gov